Background pattern of a brain with neural connections
Frances Platt

Frances Platt

Co-PI (Core Leadership)

University of Oxford

Frances Platt is an expert on glycosphingolipids (GSL) and glycosphingolipid (GSL) lysosomal storage disorders. She pioneered the first pharmacological approach to treat these disorders that she termed substrate reduction therapy (SRT). This led to the development of an approved drug (miglustat) for type 1 Gaucher disease. Miglustat was approved by the EMEA in 2002 and by the FDA in 2003 and is now in use worldwide as the first oral therapy for a lysosomal disorder. Miglustat was also approved (2009) for Niemann-Pick disease type C1 (NPC) and is the first disease-modifying therapy for this severe progressive neurodegenerative lysosomal disorder.

Recent ASAP Preprints & Published Papers

The annotation and function of the Parkinson’s and Gaucher disease-linked gene GBA1 has been concealed by its protein-coding pseudogene GBAP1

Mutations in GBA1 cause Gaucher disease and are the most important genetic risk factor for Parkinson’s disease. However, analysis of transcription at this locus is complicated by its highly homologous pseudogene, GBAP1. We show that >50% of short RNA-sequencing reads mapping to GBA1 also map to GBAP1. Thus, we used long-read RNA sequencing in the human brain, which allowed us to accurately quantify expression from both GBA1 and GBAP1. We discovered significant differences in expression compared to short-read data and identify currently unannotated transcripts of both GBA1 and GBAP1. These included protein-coding transcripts from both genes that were translated in human brain, but without the known lysosomal function—yet accounting for almost a third of transcription. Analyzing brain-specific cell types using long-read and single-nucleus RNA sequencing revealed region-specific variations in transcript expression. Overall, these findings suggest nonlysosomal roles for GBA1 and GBAP1 with implications for our understanding of the role of GBA1 in health and disease.

Analysis of glycosphingolipids from human plasma

Interest in the role of cellular glycosphingolipids (GSLs) in health and disease led to us developing a sensitive method to analyse the full complement of GSL structures present in mammalian cells, fluids and tissues. The original qualitative method we developed was published in 2004 and measured the oligosaccharides selectively released from glycosphingolipids using a ceramide glycanase enzyme derived from the medicinal leech. We have now updated and refined this protocol with the focus on achieving sensitive and reproducible quantitation of GSLs in control and patient plasma samples. The method uses the fluorescent compound anthranilic acid (2-AA) to label oligosaccharides prior to analysis using normal-phase high-performance liquid chromatography. The labelling procedure is rapid, selective, and easy to perform. With the inclusion of a 2AA-labelled chitotriose calibration standard, it is possible to obtain accurate and reproducible molar quantities of individual GSL species.

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.